DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Improving Sleep in BMT Survivors

Not Applicable

Completed

Conditions: Sleep Disturbance
Sleep Disorder

Interventions: Other: Qualitative Interviews
Other: Educational Control Condition
Other: mHealth Stepped-care Intervention
Other: Questionnaire
Other: Interview
Other: Virtual Reality

First Posted Date: 2018-05-25

Last Posted Date: 2025-04-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 30

Registration Number: NCT03537963

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention

Phase 2

Withdrawn

Conditions: Bladder Cancer
Bladder Tumor
Urothelial Carcinoma

Interventions: Other: Placebo Administration
Drug: Sulforaphane Administration
Procedure: Standard of Care Surgery

First Posted Date: 2018-05-08

Last Posted Date: 2020-05-28

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT03517995

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
James A. Haley Veteran's Administration Hospital, Tampa, Florida, United States

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Pembrolizumab
Drug: Ibrutinib

First Posted Date: 2018-05-02

Last Posted Date: 2025-05-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 5

Registration Number: NCT03514017

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

Early Phase 1

Active, not recruiting

Conditions: Advanced Prostate Cancer
Adenocarcinoma of the Prostate
Prostate Cancer
Stage IV Prostate Cancer

Interventions: Drug: Adaptive Androgen Deprivation Therapy (ADT)
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2018-04-27

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 17

Registration Number: NCT03511196

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Using MC1R Genotype to Impact Melanoma Risk Behavior

Not Applicable

Completed

Conditions: Basal Cell Carcinoma
Squamous Cell Carcinoma
Skin Cancer
Melanoma (Skin)
Squamous Cell Cancer
Basal Cell Cancer

Interventions: Behavioral: Personalized Information
Behavioral: Standard Information
Other: DNA Extraction Determination of MC1R Genotypes

First Posted Date: 2018-04-26

Last Posted Date: 2025-05-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 2054

Registration Number: NCT03509467

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇵🇷
Ponce School of Medicine, Ponce, Puerto Rico

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Phase 1

Active, not recruiting

Conditions: Melanoma
Unresectable Melanoma
Advanced Melanoma

Interventions: Drug: Ceritinib
Drug: Trametinib

First Posted Date: 2018-04-18

Last Posted Date: 2025-05-21

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT03501368

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

Phase 2

Recruiting

Conditions: Prostate Cancer
Recurrent Prostate Cancer

Interventions: Drug: F-DCFPyL Injection
Diagnostic Test: PSMA PET

First Posted Date: 2018-04-12

Last Posted Date: 2025-05-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 60

Registration Number: NCT03495427

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma
GBM
Brain Tumor

Interventions: Drug: Pembrolizumab
Drug: Vorinostat
Drug: Temozolomide
Radiation: Radiotherapy

First Posted Date: 2018-02-08

Last Posted Date: 2023-07-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 21

Registration Number: NCT03426891

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2018-01-25

Last Posted Date: 2023-03-29

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 18

Registration Number: NCT03411031

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Phase 2

Terminated

Conditions: Lung Cancer
Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Biological: Dendritic Cell based p53 Vaccine

First Posted Date: 2018-01-23

Last Posted Date: 2023-03-30

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 14

Registration Number: NCT03406715

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy